Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS…

Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial  

VANCOUVER, BC, April 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the
“Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its second quarter financial results
for the three months ended February 28, 2021.

In the second quarter, Numinus raised significant funds and advanced its compassionate access trial portfolio, acquisition strategy and innovation agenda while creating a strong foundation for
long-term, sustainable growth across all lines of business.

All financial results are reported in Canadian dollars unless otherwise stated.

Q2 2021 Highlights:

  • Achieved cash balance of $28.5 million as at February 28, 2021
  • Completed $17.25
    million
    bought deal public financing and exercised more than $14.5 million in warrants and options
  • Realized net loss of $4.2
    million
    compared to $2.1 million in Q2 2020
  • Reported revenue of $231,507 compared to $259,489
    in Q2 2020
  • Completed acquisition of Montreal-based Mindspace Wellbeing
  • Signed lab services agreement with Optimi Health to advance R&D
  • Announced collaboration with Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) and key advancements for the compassionate access trial for
    MDMA-assisted therapy for post-traumatic stress disorder
  • Completed the first legal extraction of Psilocybe mushrooms by a Canadian public company
  • Obtained the Orbitrap
    Exploris 120 mass spectrometer instrument to accelerate R&D

Highlights Subsequent to Quarter End:

  • Completed $40.25 million bought deal public financing
  • Raised $1.48 million due to the exercise of warrants and
    options
  • Achieved several milestones for the compassionate access trial with Syreon Corporation for Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use
    disorders
  • Received Health Canada license amendment to allow for the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including ketamine, LSD,
    mescaline, DMT, and MDMA
  • Announced a 7,500-square-foot expansion of Numinus Bioscience’s research laboratory
  • Continued research activities related to psilocybin extraction of
    Psilocybe mushrooms as part of the Company’s research program
  • Announced Phase 1 clinical trial of natural psilocybin mushroom extraction prepared at Company lab in partnership with
    KGK Science

Commentary and Outlook

“Q2 was a landmark quarter for Numinus, and we were pleased to close the period with a strong cash position, stable balance sheet and robust pipeline of announcements across all lines of our
business,” said Payton Nyquvest, President, CEO, and Chair, Numinus. “In addition, we were pleased to welcome Mindspace Wellbeing, its exceptional leadership team and
more than 30 therapists into our family of clinics.”

“As of today, we are well set up for the balance of the fiscal year with $65 million in cash, a strategy for future M&A, leadership in lab licensing, world-class
clinical trial partnerships and a uniquely integrated approach to psychedelic production, research and clinic care. Our focus remains on investments in our growth initiatives, and we are confident
that we will continue advancing our leadership position in the implementation of evidence-based, psychedelic-assisted therapy,” added Mr. Nyquvest. “I want to thank our team, partners and
shareholders for helping us achieve these important milestones less than one year after our public markets debut, and for supporting our mission to empower people to heal and be well.”

Numinus continues to generate revenue in its first operational year as a public company and is actively investing capital to further its growth initiatives. The Company expanded its psychedelic
testing capabilities and services at its Numinus Bioscience laboratory, and has undertaken renovations at its Vancouver clinic to offer a wider variety of therapy
options and prepare for psychedelic-assisted therapy delivery and compassionate access trials later in 2021. In addition, the Company started generating revenue from the closing of the Mindspace
acquisition in Q2.

With the capital raised in Q2 and subsequently in Q3, Numinus has a strong cash position that will be invested to support lab initiatives, Vancouver clinic
renovations and new hires, including positions in business development, M&A, marketing and communications, and mental health and psychedelic-assisted therapy services.

Selected Financial Results for Q2 2021

For the three months ended

For the six months ended

February 28,

2021

February 29,

2020

February 28,

2021

February 29,

2020

Revenue

$

231,507

$

259,489

$

460,695

$

393,904

Cost of revenue

(291,231)

(155,031)

(558,554)

(223,229)

Gross profit

(59,724)

104,458

(97,859)

170,675

Expenses

(4,170,659)

(2,135,273)

(6,080,588)

(3,092,750)

Loss before other items

(4,230,383)

(2,030,815)

(6,178,447)

(2,922,075)

Other items

(7,489)

(37,133)

11,838

(50,884)

Loss before income taxes

(4,237,872)

(2,067,948)

(6,166,609)

(2,972,959)

Income tax

(6,240)

Loss and comprehensive loss for the period

$

(4,237,872)

$

(2,067,948)

$

(6,166,609)

$

(2,979,199)

 

For the six months ended

February 28,

2021

February 29,

2020

Cash used in operating activities

$

(6,212,845)

$

(526,861)

Cash generated by (used in) investing activities

(71,847)

53,552

Cash generated by financing activities

33,238,449

584,803

Change in cash during the period

26,953,757

111,494

Cash, beginning of period

1,627,329

89,987

Cash, end of period

$

28,581,086

$

201,481

Numinus’ condensed consolidated interim financial statements for the period ended February 28, 2021 and related management’s discussion and
analysis are available on Numinus’ website at numinus.ca and under the Company’s profile on SEDAR at www.sedar.com.

About Numinus

Numinus Wellness (TSX-V: NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for
depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a
healthier society.

Learn more at numinus.ca, and
follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking
statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “Anticipates” or “does not anticipate”, or “believes” or variations of
these words, expressions or statements, that certain actions, events or results “may”, “could”, “would” or “be” taken, will occur or will be realized. Such forward-looking statements involve risks,
uncertainties and other known and unknown factors that could cause results, events or developments to differ materially from the results, events or developments expected and expressed or implied in
such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of
federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s
facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception
of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the
market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and
other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build
and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to
place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from
those described in forward-looking statements, other factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance
that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not
undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this news release.

SOURCE Numinus Wellness Inc.

Learn more about the psychedelics industry at Microdose.

Get Bi-Weekly Updates

Subscribe to the Market Insights Report

Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.

  • This field is for validation purposes and should be left unchanged.
Numinus

Numinus

We’re developing new approaches, new treatments and new ways of thinking — solutions where the world of health care and technology collide — to help individuals and communities heal, discover meaning and make deeper connections.